Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 136,124 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel sold 136,124 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at approximately $1,616,257.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Kiniksa Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ KNSA opened at $26.12 on Friday. The firm’s 50-day moving average price is $19.97 and its two-hundred day moving average price is $19.47. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $14.12 and a 52-week high of $27.88. The stock has a market capitalization of $1.85 billion, a P/E ratio of 237.48 and a beta of 0.38.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The business had revenue of $108.30 million for the quarter, compared to the consensus estimate of $90.60 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 3.10%. The business’s revenue was up 51.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.05 earnings per share for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Hhlr Advisors LTD. bought a new stake in Kiniksa Pharmaceuticals in the 1st quarter valued at about $61,868,000. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock valued at $58,833,000 after purchasing an additional 16,595 shares during the period. Granahan Investment Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals by 35.2% during the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after buying an additional 188,174 shares during the last quarter. Parkman Healthcare Partners LLC boosted its position in shares of Kiniksa Pharmaceuticals by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 615,693 shares of the company’s stock worth $10,799,000 after buying an additional 105,883 shares during the period. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth approximately $7,999,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KNSA shares. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Evercore ISI increased their target price on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Wells Fargo & Company started coverage on Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They set an “overweight” rating and a $34.00 price target on the stock. Four research analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $32.00.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.